

Dengue, Leptospira, Malaria and scrub. Data regarding the treatment, need for renal replacement therapy are collected. Patients are followed post discharge at 1 month, 3 months and 6 months. Hypertension, renal dysfunction, proteinuria, complement levels and active sediment are assessed during the time of follow up.

**Results:** Data is capulated. Final data will be presented in the WCN congress.

#### QUESTIONNAIRE

Name  
Age  
Gender  
Occupation  
Residence of  
Phone

**History of** Fever/hematuria/sore throat/skin lesions/dental caries/oliguria/hypertension/edema

Other systems- rash, joint pains, diarrhea, jaundice, seizures, bleeding

Family history of similar illness  
Epidemic or sporadic onset

**Clinical syndrome** Nephrotic-nephritic/ Acute Nephritic illness/ RPRF / AKI

**Co Morbidities** HTN/DM/CAD/TB/IV Drug abuse/ Malignancy

Investigations  
CBP  
CRP  
RFT  
LFT  
LDH  
ESR  
24 hr protein  
UPCR  
CUE  
ASO titres  
Blood culture  
Urine culture  
Dental examination  
ENT examination  
Fundus

Fever profile (in relevant cases)- Smear for Malarial parasite, Dengue IgG and IgM; NS1; Leptospira antibodies; Scrub typhus antibodies.

Complement levels (C3 and C4)

ANA and ANCA levels are done when relevant

CXR PA VIEW

USG

Renal biopsy

Renal replacement therapy

**Conclusions:** IRGN is a self limiting glomerulonephritis. Nevertheless timely follow up of cases help us understand the changing pathogenesis, pathophysiology and outcome of the patients with IRGN.

I have no potential conflict of interest to disclose.

#### WCN24-2238

### EXOSTOSIN 1- AND 2- POSITIVE MEMBRANOUS NEPHROPATHY IN CHINESE PATIENTS



Hong Cheng<sup>\*1</sup>, Guoqin Wang<sup>2</sup>, Lijun Sun<sup>2</sup>, Hongrui Dong<sup>2</sup>, Xiaoyi Xu<sup>2</sup>, Nan Ye<sup>2</sup>, Min Yang<sup>2</sup>, Yanyan Wang<sup>2</sup>, Wenrong Cheng<sup>2</sup>, Weiyi Guo<sup>2</sup>, Zhirui Zhao<sup>2</sup>, Xiaoyi Zhao<sup>3</sup>, Yanqiu Geng<sup>4</sup>, Feng Mei<sup>5</sup>

<sup>1</sup>Beijing, Renal Division, China; <sup>2</sup>Renal Division, Beijing Anzhen Hospital, Capital Medical University, Beijing; <sup>3</sup>Renal Division, Affiliated Hospital of Chifeng University, Neimenggu; <sup>4</sup>Renal Division, Third Medical Center of Chinese PLA General Hospital, Beijing; <sup>5</sup>Renal Division, Qinghai University Affiliated Hospital, Qinghai

**Introduction:** The exostosin 1 and 2 (EXT1/2) complex was recently identified as a potential antigen associated with systemic autoimmunity in PLA2R-negative membranous nephropathy patients. There are currently no reports of circulating antiEXT1/2 antibodies and no clinical studies of EXT1/2-positive membranous nephropathy in the Chinese population.

**Methods:** Immunohistochemical staining for PLA2R, THSD7A and NELL-1 was performed in 1442 consecutive patients with biopsy-proven MN from January 2011 to December 2019 at Beijing Anzhen Hospital. A total of 201 MN patients were PLA2R-, THSD7A- and

NELL-1-negative and enrolled in the study. Patient medical records were reviewed for clinical data, including demographics, laboratory tests, treatment, and follow-up. The glomerular expression of EXT1 and EXT2 was screened. The anti-EXT1 and anti-EXT2 antibodies were also detected in the sera of patients with EXT1/2-positive membranous nephropathy by western blot, ELISA and immunoprecipitation separately. Clinical and pathologic features were comparable between PLA2R-, THSD7A- and NELL-1-negative patients with EXT1/2 or without EXT1/2 positive.

**Results:** Among these 201 patients, 19 of 83 (22.9%) with lupus membranous nephropathy (class 5 and class 5+3/4), and 13 of 118 (11.0%) with nonlupus membranous nephropathy exhibited positive EXT1/2 staining. Thirteen patients with EXT1/2-positive non-LMN had no definitive secondary cause, but 7 patients (53.8%, 7/13) were seropositive for ANA. Baseline anti-double-stranded DNA antibody and serum antinuclear antibody positivity were independent predictors of glomerular EXT1/2-positive expression in patients with lupus membranous nephropathy (pure class 5, class 5 + 3/4) and nonlupus membranous nephropathy, respectively. In 32 patients with EXT1/2-positive MN, 22 patients with available serum samples collected at the time of biopsy were tested for anti-EXT1 and anti-EXT2 antibodies. Sixteen patients were positive for antibodies. According to the molecular weight of positive bands, we speculated that 5 patients were positive for both antiEXT1 and anti-EXT2 antibodies, 11 patients were positive only for anti-EXT1 antibodies, and no patients were positive only for anti-EXT2 antibodies. There were no significantly differences between the characteristics of 22 EXT1/2-positive MN patients with or without antibody seropositivity. Two patients with EXT1/2-positive membranous nephropathy underwent repeated renal biopsies. When the pathological type changed to lupus nephritis (LN) or the LN worsened clinically, the renal tissue staining intensity of EXT1/2 increased. Renal EXT1/2 staining positivity occurred earlier than the diagnosis of lupus.

**Conclusions:** This is the first study to detect circulating anti-EXT1/2 antibodies, and the functional significance should be further studied. The renal EXT1/2 staining positive was earlier than diagnosis of lupus. whether the level of serum EXT1/2 antibody can be used as a predictor for disease progression and prognosis needs to be further evaluated in larger sample studies.

I have no potential conflict of interest to disclose.

#### WCN24-2249

### CLINICOPATHOLOGICAL SPECTRUM OF BIOPSY PROVEN GLOMERULAR DISEASES REPORTED BY AN ACADEMIC CENTRE IN SRI LANKA



Dilushi Wijayaratne<sup>\*1</sup>, Harshima Wijesinghe<sup>2</sup>, Nuzha Nuha<sup>3</sup>, Gayani Ranaweera<sup>3</sup>, Priyani Amarathunga<sup>3</sup>, Champika Ratnayake<sup>4</sup>, Vindya Gunasekera<sup>5</sup>, Eranga Wijewickrama<sup>2</sup>, Chandu de Silva<sup>6</sup>

<sup>1</sup>Colombo 8, Pathology, Sri Lanka; <sup>2</sup>Medicine, Faculty of Medicine, University of Colombo, Colombo 8; <sup>3</sup>Pathology, Faculty of Medicine, University of Colombo, Colombo 8; <sup>4</sup>Pathology, Medical Research Institute, Colombo 8; <sup>5</sup>Nephrology, Lady Ridgeway Hospital, Colombo; <sup>6</sup>Pathology, Faculty of Medicine, University of Colombo, Colombo

**Introduction:** The clinical presentation of glomerular diseases (GD) can vary widely. Renal immunofluorescence (IF) has not been widely available in Sri Lanka, limiting pathological diagnosis. Electron microscopy (EM) is not available. This study was aimed at describing the clinicopathological spectrum of biopsy proven GD reported in an academic centre in Sri Lanka. The centre receives samples from the National Hospital of Sri Lanka and the Lady Ridgeway Hospital, which are tertiary care hospitals based in Colombo that cater for adult and paediatric nephrology patients. IF has been routinely performed on kidney biopsies since 2021.

**Methods:** The records of all native kidney biopsies (adult and paediatric) reported at the Department of Pathology, Faculty of Medicine, University of Colombo Sri Lanka from January 2017 to October 2023 for which both light microscopy (LM) and IF descriptions were available were reviewed.

**Results:** Of 1975 native kidney biopsies processed at the centre, data for both LM and IF was available for 468 (75 paediatric; 393 adult). Mean age of the study population was 36.5 ± 1.8 years; male: female ratio was 1:1.03. A history of diabetes, hypertension or systemic lupus erythematosus was present in 24.4% (n=114), 47.3% (n=221) and 10.3% (n=48) respectively. The commonest indication for biopsy was

